Immunome (NASDAQ:IMNM) Director Philip Wagenheim Sells 36,800 Shares

Immunome, Inc. (NASDAQ:IMNM) Director Philip Wagenheim sold 36,800 shares of the firm’s stock in a transaction on Friday, March 20th. The shares were sold at an average price of $20.47, for a total transaction of $753,296.00. Following the completion of the transaction, the director directly owned 369,347 shares in the company, valued at $7,560,533.09. This trade represents a 9.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Philip Wagenheim also recently made the following trade(s):

• On Monday, March 23rd, Philip Wagenheim sold 28,200 shares of Immunome stock. The stock was sold at an average price of $20.65, for a total transaction of $582,330.00.

Immunome Price Performance

IMNM opened at $20.75 on Tuesday. Immunome, Inc. has a fifty-two week low of $5.15 and a fifty-two week high of $27.65. The firm has a market capitalization of $2.35 billion, a PE ratio of -8.57 and a beta of 2.12. The company’s 50-day moving average is $22.76 and its 200 day moving average is $18.64.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.10). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 57.61%. As a group, analysts expect that Immunome, Inc. will post -2.21 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Evercore lifted their target price on Immunome from $18.00 to $40.00 and gave the company an “outperform” rating in a research report on Tuesday, December 16th. HC Wainwright initiated coverage on Immunome in a research report on Thursday, February 12th. They issued a “buy” rating and a $40.00 price target for the company. Leerink Partners set a $40.00 price objective on Immunome in a research note on Monday, December 15th. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Finally, Truist Financial started coverage on shares of Immunome in a research note on Monday, December 1st. They issued a “buy” rating and a $36.00 target price for the company. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $33.45.

Institutional Trading of Immunome

A number of institutional investors and hedge funds have recently modified their holdings of the business. Strs Ohio bought a new stake in Immunome during the fourth quarter worth $64,000. Assetmark Inc. bought a new position in Immunome in the 3rd quarter valued at $39,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Immunome during the 4th quarter valued at $121,000. BIT Capital GmbH purchased a new stake in shares of Immunome during the 3rd quarter valued at $69,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares during the period. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.